Bladder cancer virus therapy shows promise in early trial
NCT ID NCT07505615
First seen Apr 08, 2026 · Last updated May 17, 2026 · Updated 3 times
Summary
This study tested a new treatment called VG161, a virus designed to attack cancer cells, for people with a type of bladder cancer that came back after standard therapy. The treatment was given directly into the bladder. The main goals were to check safety, find the best dose, and see if it could help prevent the cancer from returning. The trial included 20 adults with recurrent non-muscle-invasive bladder cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMIBC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center, ShangHai,
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.